Last reviewed · How we verify
NCT03471897
Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma
trial testing Glycosaminoglycan plasma score in Renal Cell Carcinoma in 237 participants. Completed in 18 January 2018.
25 October 2017
Quick facts
| Lead sponsor | Chalmers University of Technology |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 237 |
| Start date | 28 April 2016 |
| Primary completion | 25 October 2017 |
| Estimated completion | 18 January 2018 |
Drugs / interventions tested
- Glycosaminoglycan plasma score
Conditions studied
- Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →
Sponsor
Chalmers University of Technology
Who can join
18 and older, any sex, with Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, the investigators profiled plasma glycosaminoglycans (GAGs) in a retrospective consecutive series of patients with a radiographic finding of renal mass referred to primary surgery for renal cell carcinoma (RCC). A control group was formed by measuring plasma GAGs in healthy volunteers. The primary endpoints were the specificity and sensitivity of plasma GAGs in the detection of early stage RCC in pre-surgical samples versus healthy individuals. The investigators further analyzed how plasma GAGs varied according to stage, grade, RCC histology, other renal masses, and after surgery. Finally, the investigators estimated whether plasma GAGs could be used for prediction and surveillance of RCC recurrence.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma.
Gatto F, Blum KA, Hosseini SS, Ghanaat M, et al · · 2018 · cited 28× · PMID 31158075 · DOI 10.1016/j.euo.2018.04.015
Verify or expand the search:
- PubMed search for NCT03471897
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Cell Carcinoma
Currently open trials in the same condition.
- NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
- NCT07195682 — A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) · Phase 1 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07227402 — A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6 · Phase 3 · recruiting
- NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
Other Chalmers University of Technology trials
Trials by the same sponsor.
- NCT06897241 — Personalized Metabolic Responses to Rapid, Slow and Resistant Starch · NA · recruiting
- NCT06842433 — The NUTRIOME Study - a Data-driven Precision Nutrition Intervention · NA · recruiting
- NCT06973408 — The SWITCH Dietary and Behavioural Intervention Study · NA · recruiting
- NCT06587958 — Fermented Plant-based Portfolio Diet 4 Metabolic Health · NA · completed
- NCT06992921 — Towards Personalized Nutrition With SCAPIS2-HOME · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03471897 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chalmers University of Technology
- Last refreshed: 17 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03471897.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing